Piramal Pharma swings to Q2 profit as revenue climbs 28% on CDMO demand
Piramal Pharma swung to a ₹5.58 crore profit in Q2 FY27 from a loss a year earlier, with revenue up 28% and guidance raised, TradingView reports.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Piramal Pharma returned to profitability in the second quarter of fiscal 2026-27, according to TradingView. The Indian drugmaker posted net profit of ₹5.58 crore, against a loss of ₹99.2 crore a year earlier. Revenue rose 28% year on year to ₹2,617 crore from ₹2,044 crore.
EBITDA climbed to ₹348.7 crore from ₹158.7 crore, lifting the margin to 13.3% from 7.8%, an increase of 550 basis points. The company raised its full-year revenue growth outlook to 19% to 20% and said profitability should be meaningfully higher.
The contract development and manufacturing arm drove the gains, with India and North America leading. Its Phase III pipeline grew to 28 molecules from 25, and antibody-drug conjugate service revenue jumped 51% in the first half. Shares closed at ₹198.45 on the BSE, up 1.69%.
why it matters
The swing to profit and the higher outlook point to better plant utilisation and tighter cost control at the CDMO unit, which remains the main growth engine. The company also said the expiry of its Bayer distribution agreement in December 2026 should not materially affect FY27 guidance. For the broader market the effect is limited, since this is one mid-sized company's quarterly report.
tags
instruments
sources
- Piramal Pharma Q2 Results: Firm swings to profit as revenue jumps 28%, led by CDMO growth — TradingView, 27 October 2026 at 17:32 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗